Can-Fite in R&D pact with NIH

The focus of the pact will be to identify agonists with potential therapeutic use in the treatment of autoimmune inflammatory diseases and cancer.

By SUSAN LERNER
January 25, 2006 07:04

Petah Tikva-based Can-Fite BioPharma said Tuesday it signed a cooperative research and development Agreement with the National Institute of Health in the US. The agreement relates to new small molecules that are agonists of the A(3) adenosine receptor A(3)AR, invented in the laboratory of Prof. Kenneth A. Jacobson from, which is the prime target of Can-Fite's drug development efforts. The focus of the pact will be to identify agonists with potential therapeutic use in the treatment of autoimmune inflammatory diseases and cancer.


Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection

By GLOBES, NIV ELIS

Israel Weather
  • 14 - 25
    Beer Sheva
    16 - 22
    Tel Aviv - Yafo
  • 12 - 21
    Jerusalem
    15 - 21
    Haifa
  • 19 - 36
    Elat
    17 - 28
    Tiberias